ArticleBritish journal of haematology2011
Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients.
Article in British journal of haematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party.The Korean journal of internal medicine · 2016Guideline
- Long-term clinical outcomes of patients with localized primary ocular adnexal mucosa-associated lymphoid tissue lymphoma.International journal of hematology · 2026Article
- Primary ocular-adnexal non-Hodgkin Lymphoma in a Peruvian cohort: An 18-year experience.PloS one · 2026Article
- Salvage Irradiation for Ocular Adnexal Mucosa Associated Lymphoid Tissue Lymphoma Refractory toAdvances in radiation oncology · 2025Article
- Article
- MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kinetics.Scientific reports · 2023Article
- Radiation therapy for primary orbital and ocular adnexal lymphoma.Clinical and translational radiation oncology · 2023Article
- Management of marginal zone lymphomas.Hematology. American Society of Hematology. Education Program · 2022Article
- Local recurrence as extraocular muscle lymphoma after 6 years of chronic myositis: a case report.BMC ophthalmology · 2022Article
- Review
- Clinicopathologic Characteristics Associated with Prognosis in Ocular Extranodal Marginal Zone B Cell Lymphoma.Medicina (Kaunas, Lithuania) · 2022Article
- Ocular adnexal mucosa-associated lymphoid tissue lymphoma: a narrative review.Journal of Yeungnam medical science · 2022Article
- Examining the utility of lower dose radiotherapy for localised primary ocular adnexal MALT lymphoma.Journal of medical radiation sciences · 2021Article
- Clinical features and treatment outcomes of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a single center retrospective analysis of 64 patients in China.International journal of ophthalmology · 2019Article
- Classification, diagnosis, and management of conjunctival lymphoma.Eye and vision (London, England) · 2019Review
- Clinical presentation and treatment outcomes of primary ocular adnexal MALT lymphoma in Thailand.Blood research · 2018Article
- Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell Lymphoma.Cancer research and treatment · 2018Article
- Extranodal Marginal Zone Lymphoma of Ocular Adnexa: Outcomes following Radiation Therapy.Ocular oncology and pathology · 2017Article
- Target volume dose and clinical outcome in radiotherapy for primary marginal zone lymphoma of the ocular adnexa.Molecular and clinical oncology · 2017Article
- Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences.Leukemia & lymphoma · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Extranodal marginal zone B-cell lymphoma is the most common orbital tumour. We conducted a retrospective analysis to examine: (i) the impact of initial presentation and staging on outcome and (ii) response to various treatment modalities and the effect of the latter on recurrence. Ninety patients with primary ocular adnexal marginal zone lymphoma (POAML) diagnosed at our institution between 1984 and 2009 were studied. POAML was associated with monoclonal gammopathy (13%) at presentation. Most POAML patients (86%) presented with Ann-Arbor stage I disease. Radiotherapy led to excellent local control, but relapses occurred in 18% of Ann-Arbor stage I patients during a median follow-up of 5 years. Local relapses, including secondary central nervous system (CNS) involvement, were observed in patients receiving radiation doses <30·6 Gy. No differences in relapse rate and survival were observed between patients who did or did not undergo staging bone marrow biopsy. Ann-Arbor stage II-IV disease and high lactate dehydrogenase levels were associated with shorter freedom from progression. In conclusion, POAML is an indolent lymphoma with continuous risk for relapse. Radiation doses of at least 30·6 Gy should be given in Ann-Arbor stage I disease, since lower doses may be more frequently associated with relapses, including CNS relapses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.